Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators

Bibliography

• Grimm D, Kay MA. Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther 2006;13(6):563-75
   PubMed Web of Science ®Google Scholar
• Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther 2006;13(6):541-52
   PubMed Web of Science ®Google Scholar
• Liu YP, Vink MA, Westerink JT, Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies. RNA 2010;16(7):1328-39
   PubMed Web of Science ®Google Scholar
• McCaffrey AP, Fawcett P, Nakai H, The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther 2008;16(5):931-41
   PubMed Web of Science ®Google Scholar
• Chen CC, Sun CP, Ma HI, Comparative study of anti-hepatitis B virus RNA interference by double-stranded adeno-associated virus serotypes 7, 8, and 9. Mol Ther 2009;17(2):352-9
   PubMed Web of Science ®Google Scholar
• Raper SE, Chirmule N, Lee FS, Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003;80(1-2):148-58
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391(6669):806-11
   PubMed Web of Science ®Google Scholar
• Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009;10(2):126-39
   PubMed Web of Science ®Google Scholar
• Zeng Y, Cullen BR. Efficient processing of primary microRNA hairpins by Drosha requires flanking nonstructured RNA sequences. J Biol Chem 2005;280(30):27595-603
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-8
   PubMed Web of Science ®Google Scholar
• Aigner A. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J Biotechnol 2006;124(1):12-25
   PubMed Web of Science ®Google Scholar
• Corey DR. Chemical modification: the key to clinical application of RNA interference? J Clin Invest 2007;117(12):3615-22
   PubMed Web of Science ®Google Scholar
• Grimm D, Streetz KL, Jopling CL, Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441(7092):537-41
   PubMed Web of Science ®Google Scholar
• McBride JL, Boudreau RL, Harper SQ, Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 2008;105(15):5868-73
   PubMed Web of Science ®Google Scholar
• Ehlert EM, Eggers R, Niclou SP, Verhaagen J. Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. BMC Neurosci 2010;11:20 doi:10.1186/1471-2202-11-20. Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841193/pdf/1471-2202-11-20.pdf
   PubMed Web of Science ®Google Scholar
• Witting SR, Brown M, Saxena R, Helper-dependent adenovirus-mediated short hairpin RNA expression in the liver activates the interferon response. J Biol Chem 2008;283(4):2120-8
   PubMed Web of Science ®Google Scholar
• Robbins MA, Li M, Leung I, Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol 2006;24(5):566-71
   PubMed Web of Science ®Google Scholar
• Ely A, Naidoo T, Mufamadi S, Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo. Mol Ther 2008;16(6):1105-12
   PubMed Web of Science ®Google Scholar
• Ely A, Naidoo T, Arbuthnot P. Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles. Nucleic Acids Res 2009;37(13):e91 doi:10.1093/nar/gkp446 Available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715259/pdf/gkp446.pdf
   PubMedGoogle Scholar
• Wold WSM, Horwitz MS. Adenoviruses. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. Wolters Kluwer Health/ Lippincott Williams and Wilkins, Philadelphia; 2007. p. 2395-436
   Google Scholar
• Sharma A, Li X, Bangari DS, Mittal SK. Adenovirus receptors and their implications in gene delivery. Virus Res 2009;143(2):184-94
   PubMed Web of Science ®Google Scholar
• Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993;73(2):309-19
   PubMed Web of Science ®Google Scholar
• Nalbantoglu J, Larochelle N, Wolf E, Muscle-specific overexpression of the adenovirus primary receptor CAR overcomes low efficiency of gene transfer to mature skeletal muscle. J Virol 2001;75(9):4276-82
   PubMed Web of Science ®Google Scholar
• Carlisle RC, Di Y, Cerny AM, Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 2009;113(9):1909-18
   PubMed Web of Science ®Google Scholar
• Wolff G, Worgall S, van Rooijen N, Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997;71(1):624-9
   PubMed Web of Science ®Google Scholar
• Cotter MJ, Zaiss AK, Muruve DA. Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1. J Virol 2005;79(23):14622-31
   PubMed Web of Science ®Google Scholar
• Shayakhmetov DM, Gaggar A, Ni S, Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005;79(12):7478-91
   PubMed Web of Science ®Google Scholar
• Waddington SN, McVey JH, Bhella D, Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008;132(3):397-409
   PubMed Web of Science ®Google Scholar
• Arnold J, Janoska M, Kajon AE, Genomic characterization of human adenovirus 36, a putative obesity agent. Virus Res 2010;149(2):152-61
   PubMed Web of Science ®Google Scholar
• Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000;18(7):723-7
   PubMed Web of Science ®Google Scholar
• Andersson MG, Haasnoot PC, Xu N, Suppression of RNA interference by adenovirus virus-associated RNA. J Virol 2005;79(15):9556-65
   PubMed Web of Science ®Google Scholar
• Lu S, Cullen BR. Adenovirus VA1 noncoding RNA can inhibit small interfering RNA and MicroRNA biogenesis. J Virol 2004;78(23):12868-76
   PubMed Web of Science ®Google Scholar
• Narvaiza I, Aparicio O, Vera M, Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing. J Virol 2006;80(24):12236-47
   PubMed Web of Science ®Google Scholar
• Crettaz J, Otano I, Ochoa L, Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12. J Virol 2009;83(6):2663-74
   PubMed Web of Science ®Google Scholar
• Maione D, Della Rocca C, Giannetti P, An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc Natl Acad Sci USA 2001;98(11):5986-91
   PubMed Web of Science ®Google Scholar
• Parks RJ, Chen L, Anton M, A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996;93(24):13565-70
   PubMed Web of Science ®Google Scholar
• Umana P, Gerdes CA, Stone D, Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol 2001;19(6):582-5
   PubMed Web of Science ®Google Scholar
• Palmer D, Ng P. Improved system for helper-dependent adenoviral vector production. Mol Ther 2003;8(5):846-52
   PubMed Web of Science ®Google Scholar
• Dormond E, Chahal P, Bernier A, An efficient process for the purification of helper-dependent adenoviral vector and removal of helper virus by iodixanol ultracentrifugation. J Virol Methods 2010;165(1):83-9
   PubMed Web of Science ®Google Scholar
• Schnell MA, Zhang Y, Tazelaar J, Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001;3(5 Pt 1):708-22
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Seino K, Nakayama T. The NKT cell system: bridging innate and acquired immunity. Nat Immunol 2003;4(12):1164-5
   PubMed Web of Science ®Google Scholar
• Chen Q, Wei H, Sun R, Therapeutic RNA silencing of Cys-X3-Cys chemokine ligand 1 gene prevents mice from adenovirus vector-induced acute liver injury. Hepatology 2008;47(2):648-58
   PubMed Web of Science ®Google Scholar
• Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91
   PubMed Web of Science ®Google Scholar
• Morral N, Parks RJ, Zhou H, High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther 1998;9(18):2709-16
   PubMed Web of Science ®Google Scholar
• Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004;15(12):1157-66
   PubMed Web of Science ®Google Scholar
• St George JA. Gene therapy progress and prospects: adenoviral vectors. Gene Ther 2003;10(14):1135-41
   PubMed Web of Science ®Google Scholar
• Kolb M, Inman M, Margetts PJ, Budesonide enhances repeated gene transfer and expression in the lung with adenoviral vectors. Am J Respir Crit Care Med 2001;164(5):866-72
   PubMed Web of Science ®Google Scholar
• Arnberg N. Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol 2009;19(3):165-78
   PubMed Web of Science ®Google Scholar
• Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 2001;8:1347-53
   PubMed Web of Science ®Google Scholar
• Kalyuzhniy O, Di Paolo NC, Silvestry M, Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 2008;105(14):5483-8
   PubMed Web of Science ®Google Scholar
• Smith TA, Idamakanti N, Marshall-Neff J, Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum Gene Ther 2003;14(17):1595-604
   PubMed Web of Science ®Google Scholar
• Magnusson MK, Hong SS, Boulanger P, Lindholm L. Genetic retargetting of adenoviruses: novel strategy employing ‘deknobbing’ of the fiber. J Virol 2001;75:7280-9
   PubMed Web of Science ®Google Scholar
• Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2008;16(1):16-29
   PubMed Web of Science ®Google Scholar
• Eto Y, Yoshioka Y, Mukai Y, Development of PEGylated adenovirus vector with targeting ligand. Int J Pharm 2008;354(1-2):3-8
   PubMedGoogle Scholar
• Hofherr SE, Shashkova EV, Weaver EA, Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther 2008;16(7):1276-82
   PubMed Web of Science ®Google Scholar
• Eto Y, Gao JQ, Sekiguchi F, PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 2005;7(5):604-12
   PubMed Web of Science ®Google Scholar
• Zhang F, Yao Y, Hao J, A dual-functioning adenoviral vector encoding both transforming growth factor-b3 and shRNA silencing type I collagen: construction and controlled release for chondrogenesis. J Control Release 2010;142:70-7
   PubMed Web of Science ®Google Scholar
• Chen Q, Wei H, Sun R, Therapeutic RNA silencing of Cys-X3-Cys chemokine ligand 1 gene prevents mice from adenovirus vector-induced acute liver injury. Hepatology 2008;47:648-58
   PubMed Web of Science ®Google Scholar
• Ruiz R, Witting SR, Saxena R, Morral N. Robust hepatic gene silencing for functional studies using helper-dependent adenoviral vectors. Hum Gene Ther 2009;20(1):87-94
   PubMed Web of Science ®Google Scholar
• Huang B, Schiefer J, Sass C, High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Hum Gene Ther 2007;18(4):303-11
   PubMed Web of Science ®Google Scholar
• Carmona S, Ely A, Crowther C, Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs. Mol Ther 2006;13(2):411-21
   PubMed Web of Science ®Google Scholar
• Crowther C, Ely A, Hornby J, Efficient inhibition of hepatitis B virus replication in vivo, using polyethylene glycol-modified adenovirus vectors. Hum Gene Ther 2008;19(11):1325-31
   PubMed Web of Science ®Google Scholar
• Uprichard SL. The therapeutic potential of RNA interference. FEBS Lett 2005;579(26):5996-6007
   PubMed Web of Science ®Google Scholar
• McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005;19(1):3-23
   PubMed Web of Science ®Google Scholar
• Arbuthnot P, Ely A. Advances in the use of RNAi to treat chronic hepatitis B virus infection. In: Martinez MA, editor. RNA Interference and viruses. Caister Academic Press, Norfolk, UK; 2010. p. 143-60
   Google Scholar
• Arbuthnot P, Thompson LJ. Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. World J Gastroenterol 2008;14(11):1670-81
   PubMed Web of Science ®Google Scholar
• McCaffrey AP, Nakai H, Pandey K, Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003;21(6):639-44
   PubMed Web of Science ®Google Scholar
• Weinberg MS, Ely A, Barichievy S, Specific inhibition of HBV replication in vitro and in vivo with expressed long hairpin RNA. Mol Ther 2007;15(3):534-41
   PubMed Web of Science ®Google Scholar
• Giladi H, Ketzinel-Gilad M, Rivkin L, Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 2003;8(5):769-76
   PubMed Web of Science ®Google Scholar
• Hamasaki K, Nakao K, Matsumoto K, Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett 2003;543(1-3):51-4
   PubMed Web of Science ®Google Scholar
• Klein C, Bock CT, Wedemeyer H, Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 2003;125(1):9-18
   PubMed Web of Science ®Google Scholar
• Konishi M, Wu CH, Wu GY. Inhibition of HBV replication by siRNA in a stable HBV-producing cell line. Hepatology 2003;38(4):842-50
   PubMed Web of Science ®Google Scholar
• Carmona S, Jorgensen MR, Kolli S, Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm 2009;6(3):706-17
   PubMedGoogle Scholar
• Uprichard SL, Boyd B, Althage A, Chisari FV. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci USA 2005;102(3):773-8
   PubMed Web of Science ®Google Scholar
• Carmona S, Jorgensen MR, Kolli S, Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm 2009;6(3):706-17
   PubMedGoogle Scholar
• Rauschhuber C, Xu H, Salazar FH, Exploring gene-deleted adenoviral vectors for delivery of short hairpin RNAs and reduction of hepatitis B virus infection in mice. J Gene Med 2008;10(8):878-89
   PubMed Web of Science ®Google Scholar
• Aurisicchio L, Delmastro P, Salucci V, Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis. J Virol 2000;74(10):4816-23
   PubMed Web of Science ®Google Scholar
• Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20(1):1-16
   PubMed Web of Science ®Google Scholar
• Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436(7053):967-72
   PubMed Web of Science ®Google Scholar
• Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004;63:71-180
   PubMed Web of Science ®Google Scholar
• Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol 2005;79(15):9369-80
   PubMed Web of Science ®Google Scholar
• Mercer DF, Schiller DE, Elliott JF, Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7(8):927-33
   PubMed Web of Science ®Google Scholar
• Kronke J, Kittler R, Buchholz F, Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J Virol 2004;78(7):3436-46
   PubMed Web of Science ®Google Scholar
• Randall G, Rice CM. Interfering with hepatitis C virus RNA replication. Virus Res 2004;102(1):19-25
   PubMed Web of Science ®Google Scholar
• Takigawa Y, Nagano-Fujii M, Deng L, Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome. Microbiol Immunol 2004;48(8):591-8
   PubMed Web of Science ®Google Scholar
• Wang Q, Contag CH, Ilves H, Small hairpin RNAs efficiently inhibit hepatitis C IRES-mediated gene expression in human tissue culture cells and a mouse model. Mol Ther 2005;12(3):562-8
   PubMed Web of Science ®Google Scholar
• Yokota T, Sakamoto N, Enomoto N, Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 2003;4(6):602-8
   PubMed Web of Science ®Google Scholar
• Akashi H, Miyagishi M, Yokota T, Escape from the interferon response associated with RNA interference using vectors that encode long modified hairpin-RNA. Mol BioSyst 2005;1:382-90
   PubMed Web of Science ®Google Scholar
• Watanabe T, Sudoh M, Miyagishi M, Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype. Gene Ther 2006;13(11):883-92
   PubMed Web of Science ®Google Scholar
• Randall G, Panis M, Cooper JD, Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci USA 2007;104(31):12884-9
   PubMed Web of Science ®Google Scholar
• Tai AW, Benita Y, Peng LF, A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 2009;5(3):298-307
   PubMed Web of Science ®Google Scholar
• Lanford RE, Hildebrandt-Eriksen ES, Petri A, Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2009;327(5962):198-201
   PubMed Web of Science ®Google Scholar
• Arbuthnot P, Ely A, Weinberg MS. Hepatic delivery of RNA interference activators for therapeutic application. Curr Gene Ther 2009;9(2):91-103
   PubMed Web of Science ®Google Scholar
• Cullen BR. Viruses and microRNAs. Nat Genet 2006;38(Suppl):S25-30
   PubMedGoogle Scholar